Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Healius Limited ( (AU:HLS) ).
Healius Limited has announced that Professor John Mattick ceased to be a director of the company effective 31 March 2026, lodging a final notice of his relevant interests in the company’s securities. The filing discloses that Mattick directly holds 4,136 ordinary shares and has additional indirect interests through custodial and retirement fund arrangements, with no interests in any related contracts, signalling a routine governance update for the healthcare operator.
The notice details indirect holdings of 235,088 shares via Bond Street Custodians Ltd for the J&L Mattick Retirement Fund and 15,093 shares via Citicorp Nominees Pty Ltd, clarifying his total equity exposure as he leaves the board. While the announcement does not indicate any immediate operational changes, it formalises a board transition that may precede further refreshment of Healius’s governance structure and will be noted by investors tracking director alignment and ownership.
The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.53 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian healthcare company operating primarily in diagnostics and medical services. The group provides pathology, imaging and related health services across a national network, serving hospitals, clinicians and patients in both metropolitan and regional markets.
Average Trading Volume: 3,150,437
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$406.6M
Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.